Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564444 | 0.82 | QPCT (0.45) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL2039668 | 0.81 | L3MBTL1 (0.44) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL15624621 | 0.79 | QPCT (0.43) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL23995209 | 0.78 | QPCT (0.42) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL30970996 | 0.78 | QPCT (0.42) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL30414649 | 0.78 | QPCT (0.42) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL3767625 | 0.78 | QPCT (0.54) | QPCTQPCTLALDH1A1PTGES2MAPT | |
| SCHEMBL31598810 | 0.78 | PTGES2 (0.58) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL27594528 | 0.77 | QPCT (0.44) | GABRG2GABRB3GABRA2QPCTQPCTL | |
| SCHEMBL30961410 | 0.76 | QPCT (0.44) | GABRG2GABRB3GABRA2QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20150293078-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-15 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| CN-101006076-B | Modulators of ATP-binding cassette transporters | VERTEX PHARMA | 2010-09-29 | — | — | CN | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| CN-101006076-A | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | GABRG2 1322/4885GABRB3 1282/4885GABRA2 1747/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | GABRG2 1322/4885GABRB3 1282/4885GABRA2 1747/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | GABRG2 1258/4885GABRB3 345/4885GABRA2 1025/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | GABRG2 894/4885GABRB3 295/4885GABRA2 853/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | GABRG2 651/4885GABRB3 282/4885GABRA2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.